Correlations of amyloid-beta concentrations between CSF and plasma in acute Alzheimer mouse model

Abstract

Amyloid-beta (A beta) is one of the few neuropathological biomarkers associated with transporters of the blood-brain barrier (BBB). Despite the well-characterized clinical indication of decreasing A beta levels in the cerebrospinal fluid (CSF) during the development of Alzheimer's disease (AD), the link between the alternation of A beta level in the blood and the progress of the disorder is still controversial. Here, we report a direct correlation of A beta(1-42) levels between CSF and plasma in AD mouse model. We injected monomeric A beta(1-42) directly into the intracerebroventricular (ICV) region of normal adult mouse brains to induce AD-like phenotypes. Using sandwich enzyme-linked immunosorbent assays, we observed proportional elevation of A beta(1-42) levels in both CSF and plasma in a dose-dependent manner. Our findings that plasma A beta(1-42) reflects the condition of CSF A beta(1-42) warrant further investigation as a biomarker for the blood diagnosis of AD.